Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance of [14C]SHR7280 in Healthy Volunteers
NCT06408948Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR7280 in infertility, sponsored by Hengrui. Primary endpoints: Cumulative recovery and recovery rate of total radioactive substance in urine and feces, Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC) and 5 more. Started Jun 2024; status: completed.
02
Drugs
SHR7280
03
Conditions
infertility
Beyond the preview
Go deeper on NCT06408948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06408948.